On

OncoImmunology

OncoImmunology is a dynamic, high-profile, open access journal covering tumor immunology and immunotherapy, including basic and translational studies in solid and hematological malignancies, immune responses against cancer, cancer immunoediting and immune evasion, modern immunotherapies, and immunological effects of conventional anticancer therapies.

Looking to publish in OncoImmunology? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Try Livewrite Now
Subject Immunology, Oncology
Impact Factor 6.3
Quartile Q1
Open Access Type Open
ISSN 2162-402X
eISSN 2162-402X
Invitation Only Yes
Cost Range Article Publishing Charge (APC) required for open access publication; institutional agreements, discounts, and waivers may reduce or cover the APC

Submission Instructions

OncoImmunology is an invitation-only journal. Submissions are accepted by invitation from the editorial board only. The following article types are accepted:

Research Article

Cover Letter Cover Letter requirements are not specified.
Abstract Abstract is required. Abstract must be 250 words. Abstract must be unstructured.
Manuscript Manuscript must be no more than 5,000 words. Manuscript must be ordered as title page, abstract, keywords, introduction, materials and methods, results, discussion, acknowledgments, declaration of interest statement, references, appendices as appropriate, tables with captions on individual pages, figures, and figure captions as a list. Manuscript must include keywords and a declaration of interest statement.
References References must not exceed 80. References may be in any consistent scholarly citation style or format. References must include complete bibliographic details and every entry must have a corresponding in-text citation.
Figures & Tables Figures and tables are limited to a combined maximum of 8, with additional figures or tables permitted as supplementary material. Figures and tables may be placed within the text or submitted as separate documents.
Reformat to OncoImmunology using Livewrite Premium

Review Articles

Cover Letter Cover Letter requirements are not specified.
Abstract Abstract is required. Abstract must be 250 words. Abstract must be unstructured.
Manuscript Manuscript must be no more than 5,000 words. Manuscript must be ordered as title page, abstract, keywords, introduction, materials and methods, results, discussion, acknowledgments, declaration of interest statement, references, appendices as appropriate, tables with captions on individual pages, figures, and figure captions as a list. Manuscript must include keywords and a declaration of interest statement.
References References may be in any style or format if a consistent scholarly citation format is used. References must include the author name or names, journal or book title, article or chapter title, year of publication, volume and issue where appropriate, and page numbers, and every bibliographic entry must have a corresponding in-text citation.
Figures & Tables A maximum of 6 figures and tables combined is permitted, with additional figures or tables allowed in supplementary material. Tables with captions must appear on individual pages, followed by figures and then figure captions as a list.
Reformat to OncoImmunology using Livewrite Premium

Brief Reports

Cover Letter Cover Letter requirements are not specified.
Abstract Abstract is required. Abstract must be 200 words. Abstract must be unstructured.
Manuscript Manuscript must be ordered as title page, abstract, keywords, prior presentations of the work, main text with Introduction, Materials and Methods, Results, and Discussion, acknowledgments, declaration of interest statement, references, appendices as appropriate, tables with captions on individual pages, figures, and figure captions as a list. Manuscript must include 5 to 10 keywords and a declaration of interest statement.
References References must not exceed 30. References may be in any consistent scholarly citation style or format. References must include author name or names, journal or book title, article or chapter title, year of publication, volume and issue where appropriate, and page numbers, and every bibliographic entry must have a corresponding in-text citation.
Figures & Tables There must be no more than 3 display items in total, with additional figures or tables allowed as supplementary material. Figures and tables may be placed within the text or submitted as separate documents.
Reformat to OncoImmunology using Livewrite Premium

Recent Publications

CXCL13-expressing CD4 + T cells coordinate the lymphocytes triad to promote the anti-tumor immunity in NSCLC

Danping Liu, Jiajun Luo, Wei Guo, Junrui Ma, Xiaobao Yang, Yihan Xia, Pu Li, Dakang Xu, Zhidong Gu

10.1080/2162402x.2026.2684116
View Publication

FTL008.16, a 5T4-Conditional 4-1BB bispecific antibody, potently enhances antitumor immunity via tumor-directed t-cell activation

Shuang Liu, Ziqing Ren, Yongyan Tu, Pengyu Chen, Yinglu Zhang, Shengyan Zhao, Xiaofeng Chen, Han Deng, Shuyun Yang, Feng Qu, Ming Zhang, Lantu Gou, Qing Li, Ying Huang, Fanxin Ma, Jinliang Yang

10.1080/2162402x.2026.2684136
View Publication

CD4 + cell depletion accelerates dendritic cell migration and enhances resident dendritic cell proliferation in tumor-draining lymph nodes

Taiki Moriya, Mayuko Hashimoto, Mizuki Ueda, Tatsuya Aoyagi, Ayako Kawaguchi, Kentaro Takahashi, Kobayashi Tsukasa, Kazuki Doi, Hiroaki Hemmi, Tsuneyasu Kaisho, Satoshi Ueha, Koji Matsushima, Yutaka Kusumoto, Tatyana Chtanova, Michio Tomura

10.1080/2162402x.2026.2682054
View Publication

Local delivery of SBRT and IL-12 to murine PDAC tumors modulates hematopoiesis

Tara G. Vrooman, Emily R. Quarato, Gary Hannon, Noah A. Salama, Maggie L. Lesch, Angela L. Hughson, Vedika S. Chandak, Nataliia Vdovichenko, Zhiming Jin, Ronald Lakony, Jian Ye, Sarah L. Eckl, Sidney Lesser, Edith M. Lord, David C. Linehan, Haoming Qiu, Nadia Luheshi, Jim Eyles, Laura M. Calvi, Scott A. Gerber

10.1080/2162402x.2026.2682058
View Publication

Dectin-1 signaling promotes Galectin-3 shedding and expansion of immunosuppressive CD71+ erythroid cells in breast cancer

Ako Azimi, Amirhossein Rahmati, Shima Shahbaz, Zahra Elahi, Alireza Zahiriabyaneh, Junyan Cao, Ernesto Luisito Padua, Chloe Church, Emmanuel T. Alimo, Afsaneh Lavasanifar, John Walker, Shokrollah Elahi

10.1080/2162402x.2026.2682649
View Publication

Frequently asked questions

How long does it take to publish?

3 days avg. from submission to first decision; 47 days avg. from submission to first post-review decision; 15 days avg. from acceptance to online publication.

Reformat to OncoImmunology using Livewrite Premium

Is a cover letter required?

A cover letter is supported and guidance is provided, but it is not stated as required.

Reformat to OncoImmunology using Livewrite Premium

What are the publication costs?

Article Publishing Charge (APC) may be required for publication. Institutional agreements, discounts, and waivers may reduce or cover the APC.

Reformat to OncoImmunology using Livewrite Premium

Research Topics

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses Immune Cell Function and Interaction CAR-T cell therapy research Immune cells in cancer T-cell and B-cell Immunology Virus-based gene therapy research Monoclonal and Polyclonal Antibodies Research Immune Response and Inflammation Phagocytosis and Immune Regulation Cancer Cells and Metastasis Cancer Research and Treatments RNA Interference and Gene Delivery vaccines and immunoinformatics approaches Chemokine receptors and signaling interferon and immune responses Lymphoma Diagnosis and Treatment Ferroptosis and cancer prognosis Cancer, Stress, Anesthesia, and Immune Response Cytokine Signaling Pathways and Interactions Pancreatic and Hepatic Oncology Research Glioma Diagnosis and Treatment Cancer, Hypoxia, and Metabolism Adenosine and Purinergic Signaling Peptidase Inhibition and Analysis

Related Journals

IJ
International Journal of Clinical Oncology Springer Science+Business Media
CC
Cancer Communications WILEY
BC
Blood Cancer Discovery American Association for Cancer Research
CH
Current HIV Research Bentham Science Publishers
CC
Current Cancer Drug Targets Bentham Science Publishers
I&
Immunity & Ageing BioMed Central